

Dear NICE,

Thanks for asking the British Thoracic Society to comment on this ACD. Whilst we are disappointed that a promising treatment for lung cancer patients has not passed the cost-effectiveness test, we feel that overall this is a fair judgement which does take all the relevant evidence into account and is therefore a suitable basis for guidance to the NHS.



On behalf of the British Thoracic Society Lung Cancer and Mesothelioma Specialist Advisory Group